Literature DB >> 10160090

The decision rules of cost-effectiveness analysis.

G Karlsson1, M Johannesson.   

Abstract

It has become increasingly popular to carry out cost-effectiveness analyses in economic evaluations of healthcare programmes. Cost-effectiveness analysis is based on the maximisation of the health effects for a given amount of resources. However, many published studies fail to report the results of cost-effectiveness analysis in a way that is consistent with this underlying aim. The aim of this article is to demonstrate the decision rules of cost-effectiveness analysis in an easily accessible way for practitioners in the field. A hypothetical example is used to demonstrate the decision rules of cost-effectiveness analysis, and we also show how to estimate the appropriate incremental cost-effectiveness ratios and how to exclude dominated alternatives. It is then shown how fixed budgets or predetermined prices per effectiveness unit can be used as decision rules to maximise health effects and to determine which programmes to implement on the basis of incremental cost-effectiveness ratios. We hope that the article will contribute towards an increased understanding and application of the appropriate decision rules of cost-effectiveness analysis, so that the results of cost-effectiveness analyses can be interpreted meaningfully by decision makers.

Mesh:

Year:  1996        PMID: 10160090     DOI: 10.2165/00019053-199609020-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.

Authors:  L Garattini; R Grilli; D Scopelliti; L Mantovani
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

2.  On the decision rules of cost-effectiveness analysis.

Authors:  M Johannesson; M C Weinstein
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

3.  Principles of cost-effective resource allocation in health care organizations.

Authors:  M C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

4.  The relationship between cost-effectiveness analysis and cost-benefit analysis.

Authors:  M Johannesson
Journal:  Soc Sci Med       Date:  1995-08       Impact factor: 4.634

5.  Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers.

Authors:  H Sintonen; V Alander
Journal:  J Health Econ       Date:  1990-06       Impact factor: 3.883

6.  The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.

Authors:  I Kawachi; L A Malcolm
Journal:  J Hypertens       Date:  1991-03       Impact factor: 4.844

7.  Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.

Authors:  M J Buxton; B J O'Brien
Journal:  Br J Cancer Suppl       Date:  1992-12
  7 in total
  30 in total

Review 1.  A review of alternative approaches to healthcare resource allocation.

Authors:  S Petrou; J Wolstenholme
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

2.  The HAART side of resource allocation.

Authors:  Pedram Sendi; Amiram Gafni
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

3.  Cost effectiveness and the allocation of therapies in a treating population.

Authors:  P C Langley
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 4.  Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?

Authors:  Andrew H Briggs; Adrian R Levy
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Bridging the gap between health and non-health investments: moving from cost-effectiveness analysis to a return on investment approach across sectors of economy.

Authors:  Pedram Sendi
Journal:  Int J Health Care Finance Econ       Date:  2008-03-20

6.  Cost-effectiveness league tables: valuable guidance for decision makers?

Authors:  Josephine Mauskopf; Frans Rutten; Warren Schonfeld
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.

Authors:  A E Duggan; K Tolley; C J Hawkey; R F Logan
Journal:  BMJ       Date:  1998-05-30

9.  Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

10.  Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Authors:  Helena Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Daniel Rea; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Sophie Gasson; Claire Balmer; Jean E Abraham; Carlos Caldas; Peter Hall; Bethany Shinkins; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.